Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
OM 
Outset Medical Inc (OM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: OM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -4.17% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 193.10M USD | Price to earnings Ratio - | 1Y Target Price 37.5 |
Price to earnings Ratio - | 1Y Target Price 37.5 | ||
Volume (30-day avg) 101494 | Beta 2.01 | 52 Weeks Range 5.85 - 78.30 | Updated Date 04/1/2025 |
52 Weeks Range 5.85 - 78.30 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -36.9 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -112.57% | Operating Margin (TTM) -55.33% |
Management Effectiveness
Return on Assets (TTM) -22.86% | Return on Equity (TTM) -170.97% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 238930520 | Price to Sales(TTM) 1.7 |
Enterprise Value 238930520 | Price to Sales(TTM) 1.7 | ||
Enterprise Value to Revenue 2.1 | Enterprise Value to EBITDA -0.24 | Shares Outstanding 17699600 | Shares Floating 2773914 |
Shares Outstanding 17699600 | Shares Floating 2773914 | ||
Percent Insiders 0.9 | Percent Institutions 18.84 |
Analyst Ratings
Rating 4.2 | Target Price 3.75 | Buy - | Strong Buy 3 |
Buy - | Strong Buy 3 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Outset Medical Inc
Company Overview
History and Background
Outset Medical was founded in 2011. The company focuses on developing and commercializing innovative technologies for dialysis. Their primary goal is to improve the patient experience and reduce the overall cost of dialysis care.
Core Business Areas
- Tablo Hemodialysis System: The Tablo system is Outset's core product, designed as a versatile, all-in-one dialysis system for use in hospitals, clinics, and patients' homes. It integrates water purification and dialysis fluid preparation.
- Services and Support: Outset also provides services and support for the Tablo system, including training, maintenance, and technical assistance.
Leadership and Structure
The leadership team includes Leslie Trigg (CEO) and diverse experienced executives. The company has a typical structure for a medical device manufacturer with departments including R&D, Sales, Marketing, and Operations.
Top Products and Market Share
Key Offerings
- Tablo Hemodialysis System: Tablo is Outset's primary product, an all-in-one hemodialysis system that simplifies dialysis treatment. While precise market share data is dynamic, Tablo aims to capture a significant portion of the dialysis market. Competitors include Fresenius Medical Care, DaVita, and Baxter.
Market Dynamics
Industry Overview
The dialysis market is substantial and growing, driven by the increasing prevalence of kidney disease. The industry is characterized by a high degree of consolidation and technological innovation.
Positioning
Outset Medical aims to disrupt the traditional dialysis market with its innovative Tablo system, emphasizing ease of use, versatility, and reduced costs. They aim to compete on innovation and patient experience.
Total Addressable Market (TAM)
The TAM for dialysis products and services is estimated to be multi-billion USD annually. Outset is positioned to capture a growing share of this market through its innovative technology and focus on home dialysis.
Upturn SWOT Analysis
Strengths
- Innovative Tablo system
- All-in-one design simplifies dialysis
- Potential for cost reduction
- Strong focus on patient experience
Weaknesses
- High capital expenditure
- Reliance on Tablo adoption
- Dependence on regulatory approvals
- Limited brand awareness compared to established players
Opportunities
- Expansion into home dialysis market
- Partnerships with healthcare providers
- Technological advancements
- Growing prevalence of kidney disease
Threats
- Competition from established players
- Reimbursement pressures
- Technological obsolescence
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- FMS
- DVA
- BAX
Competitive Landscape
Outset Medical aims to differentiate itself through innovation and ease of use. Established players benefit from larger market share and extensive networks, but Outset is poised to capture market share with its innovative technology.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Data not available in real time. Consult financial data provider to obtain current financials. Analyze historical revenue growth and adoption of Tablo.
Future Projections: Analyst estimates suggest continued growth driven by adoption of Tablo in hospitals, clinics, and homes. Growth will depend on regulatory approvals and market penetration.
Recent Initiatives: Outset focuses on expanding its commercial reach, improving its technology, and securing regulatory approvals for new applications of the Tablo system.
Summary
Outset Medical is an innovative company that is working to disrupt the dialysis market. The Tablo system has the potential to significantly improve the patient experience and reduce costs. Challenges remain in adoption, competition, and regulatory hurdles. Key strengths are its innovative technology and the potential for cost reduction. However it is important to closely watch its cash burn and how fast it grows
Similar Companies
BAX
Baxter International Inc
BAX
Baxter International Inc
DVA
DaVita HealthCare Partners Inc
DVA
DaVita HealthCare Partners Inc
FMS
Fresenius Medical Care Corporation
FMS
Fresenius Medical Care Corporation
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry research
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary depending on the source. Financial data is not real-time. Consult a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Outset Medical Inc
Exchange NASDAQ | Headquaters San Jose, CA, United States | ||
IPO Launch date 2020-09-15 | President, CEO & Chairman Ms. Leslie L. Trigg | ||
Sector Healthcare | Industry Medical Devices | Full time employees - | Website https://www.outsetmedical.com |
Full time employees - | Website https://www.outsetmedical.com | ||
Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.